GENEVA, Switzerland, January 30 /PRNewswire-FirstCall/ -- - easypod(R) Was Designed to Improve Ease of Usage, Reliability and Convenience Merck...
ONWARD Phase II Trial Will Assess Therapeutic Benefit of Oral Cladribine Added-on to New Formulation of Rebif(R) in Multiple Sclerosis Patients...
Phenoptin Significantly Increases Phenylalanine Tolerance in BH4-Responsive Patients; All Pre-Specified Endpoints Met GENEVA, Switzerland...
Oral Cladribine on Track to Become First Oral Disease Modifying Treatment for Multiple Sclerosis GENEVA, Switzerland, January 16...
Top Management Appointed GENEVA, Switzerland, January 8 /PRNewswire-FirstCall/ -- Following the successful closing of the Share Purchase...
SEATTLE, Washington and GENEVA, Switzerland, December 20 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) and Serono (virt-x: SEO and...
GENEVA, Switzerland, December 18 /PRNewswire-FirstCall/ -- Serono (virt-x: SEO and NYSE: SRA) has today been informed that Merck KGaA of...
First Trial Assessing Therapeutic Benefit of Two Different Dosage Regimens of Disease Modifying Therapy in People With First Clinical Symptoms...
Clear Biologic Activity, Tolerability and Trends Toward Efficacy Observed SEATTLE, Washington and GENEVA, Switzerland, November 13...
Excellent Performance of Rebif(R) With Sales Up 18.7% to $374.8m GENEVA, Switzerland, October 19 /PRNewswire-FirstCall/ -- Serono (virt-x: SEO...
GENEVA, Switzerland and MILAN, Italy, October 16 /PRNewswire-FirstCall/ -- Serono (virt-X: SEO and NYSE: SRA) and Newron Pharmaceuticals SpA...
CARLSBAD, California and GENEVA, Switzerland, October 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (NASDAQ:MITI), a biopharmaceutical company...
Data Presented at 22nd ECTRIMS Congress in Madrid MADRID, Spain, September 28 /PRNewswire-FirstCall/ -- Serono (virt-x: SEO and NYSE: SRA...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.